Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.

Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
复制标题

DOI:
10.1177/0269881111405366
复制
发表时间:
2011-08
期刊:
Journal of psychopharmacology (Oxford, England)
影响因子:
--
通讯作者:
Potier MC
Potier MC
中科院分区:
其他
文献类型:
--
作者:
Braudeau J;Delatour B;Duchon A;Pereira PL;Dauphinot L;de Chaumont F;Olivo-Marin JC;Dodd RH;Hérault Y;Potier MC

文献摘要

参考文献

被引文献

相似文献

抑制性和兴奋性神经传递之间的不平衡一直是 建议有助于改变唐氏症患者的大脑功能 综合征(DS)。γ-氨基丁酸(GABA)是主要的抑制剂, 中枢神经系统中的神经递质,并因此用 GABA-A拮抗剂可有效恢复Ts 65 Dn小鼠的认知功能, DS的遗传模型。然而,GABA-A拮抗剂也是惊厥性的, 排除其用于DS个体的治疗干预。这里有 评估了使用一种更安全的策略来释放GABA能抑制, 选择性α5亚型GABA-A-苯二氮卓受体反向激动剂 (α5IA)。我们证明,α5IA恢复学习和记忆功能, Ts 65 Dn小鼠的新物体识别和Morris水迷宫任务。 此外,我们发现,行为刺激后,α5IA增强, 学习诱发的大脑特定区域的即刻早期基因产物 在认知方面。重要的是,α5IA的急性和慢性治疗不会诱导 任何与GABA-A拮抗剂相关的惊厥或焦虑作用 或GABA-A-苯并二氮杂受体的非选择性反向激动剂。 最后,α5IA的长期治疗没有诱导组织学改变, 小鼠的大脑、肝脏和肾脏。我们的研究结果表明, α5选择性GABA-A反向激动剂可改善学习记忆障碍 在DS个人。
An imbalance between inhibitory and excitatory neurotransmission has been proposed to contribute to altered brain function in individuals with Down syndrome (DS). Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system and accordingly treatment with GABA-A antagonists can efficiently restore cognitive functions of Ts65Dn mice, a genetic model for DS. However, GABA-A antagonists are also convulsant which preclude their use for therapeutic intervention in DS individuals. Here, we have evaluated safer strategies to release GABAergic inhibition using a GABA-A-benzodiazepine receptor inverse agonist selective for the α5-subtype (α5IA). We demonstrate that α5IA restores learning and memory functions of Ts65Dn mice in the novel-object recognition and in the Morris water maze tasks. Furthermore, we show that following behavioural stimulation, α5IA enhances learning-evoked immediate early gene products in specific brain regions involved in cognition. Importantly, acute and chronic treatments with α5IA do not induce any convulsant or anxiogenic effects that are associated with GABA-A antagonists or non-selective inverse agonists of the GABA-A-benzodiazepine receptors. Finally, chronic treatment with α5IA did not induce histological alterations in the brain, liver and kidney of mice. Our results suggest that non-convulsant α5-selective GABA-A inverse agonists could improve learning and memory deficits in DS individuals.
DOI: 10.1016/j.neuropharm.2006.04.018
发表时间: 2006-11-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Atack, John R.;Bayley, Peter J.;Dawson, Gerard R.
通讯作者: Dawson, Gerard R.
DOI: 10.1016/s0028-3908(97)00157-3
发表时间: 1997-11-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Siarey, RJ;Stoll, J;Galdzicki, Z
通讯作者: Galdzicki, Z
DOI: 10.1523/jneurosci.1766-04.2004
发表时间: 2004-09-15
影响因子: 5.3
作者:
Kleschevnikov, AM;Belichenko, PV;Mobley, WC
通讯作者: Mobley, WC
DOI: 10.1016/j.neuropharm.2007.08.008
发表时间: 2007-12-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Nutt, David J.;Besson, Marie;Lingford-Hughes, Anne R.
通讯作者: Lingford-Hughes, Anne R.
DOI: 10.1016/s0166-4328(97)81111-4
发表时间: 1996-12-01
影响因子: 2.7
作者:
Demas, GE;Nelson, RJ;Yarowsky, OJ
通讯作者: Yarowsky, OJ